Formulary Group work programme


Forthcoming submissions 2015

This list is indicative and may be subject to change.

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Aztreonam lysine - SMC 753/12 - Formulary Group advice will be published by 3rd February 2015. (Indication: suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older).

Botox® - FG1 374/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: chronic migraine).

Brentuximab - SMC 845/12 - in progress. (Indication: treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)).

Brimonidine - SMC 1016/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: the symptomatic treatment of facial erythema of rosacea in adult patients).

Canagliflozin plus metformin (Vokanamet®) - SMC 1019/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control).

Cetuximab - SMC 1012/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer).

Dolutegravir, abacavir, lamivudine (Triumeq®) - SMC 1009/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg).

Ganciclovir eye gel - FG1 375/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: local treatment of herpes simplex infection (ocular)).

Nalmefene - SMC 917/13 - in progress. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Obinutuzumab - SMC 1008/14 - in progress. (Indication: in combination with chlorambucil, obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy).

Ocriplasmin - SMC 892/13 - in progress. (Indication: in adults for the treatment of vitreomacular traction).

Olodaterol - SMC 974/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease).

Omalizumab - SMC 1017/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations: management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Peginterferon beta 1a - SMC 1018/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: in adult patients for the treatment of relapsing remitting multiple sclerosis).

Pomalidomide - SMC 972/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma).

Posaconazole - SMC 999/14 - Formulary Group advice will be published by 3rd February 2015. (Indication: the treatment of fungal infections in adults).

Rituximab subcutaneous injection - SMC 975/14 - in progress. (Indication: for non-Hodgkin's lymphoma (NHL) in adults).

Triamcinolone - FG1 363/14 - in progress. (Indication: Cystoid Macular Oedema (CMO)).


Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »